Transplantation pulmonaire en France : actualisation des indications et contre-indications en 2022
Abstract
Lung transplantation (LTx) is the last-resort treatment for end-stage respiratoryinsufficiency, whatever its origin, and represents a steadily expanding field of endeavor. Major developments have been impelled over the years by painstaking efforts at LTx centers to improve donor and recipient selection, and multifaceted attempts have been madeto meet the challenges raised by surgical management, perioperative care, and long-termmedical complications. The number of procedures has increased, leading to improved post-LTx prognosis. One consequence of these multiple developments has been a pruning away ofcontraindications over time, which has, in some ways, complicated the patient selection process. With these considerations in mind, the Francophone Pulmonology Society (Societe dePneumology de Langue Francaise [SPLF]) has set up a task force to produce up-to-date workingguidelines designed to assist pulmonologists in managing end-stage respiratory insufficiency, determining which patients may be eligible for LTx, and appropriately timing LTx-center referral. The task force has examined the most recent literature and evaluated the risk factors thatcontinue to limit patient survival after LTx. Ideally, the objectives of LTx are to prolong lifewhile improving quality of life. The guidelines developed by the task force apply to a limitedresource and are consistent with the ethical principles described below.